Marathe, Sandesh J. https://orcid.org/0000-0003-4859-3055
Grey, Emily W. https://orcid.org/0000-0003-1153-7471
Bohm, Margaret S. https://orcid.org/0000-0001-7409-7798
Joseph, Sydney C. https://orcid.org/0000-0003-3606-5650
Ramesh, Arvind V. https://orcid.org/0009-0005-2977-5787
Cottam, Matthew A. https://orcid.org/0000-0003-0619-1605
Idrees, Kamran https://orcid.org/0000-0003-0911-4461
Wellen, Kathryn E. https://orcid.org/0000-0002-2281-0042
Hasty, Alyssa H. https://orcid.org/0000-0001-7302-8045
Rathmell, Jeffrey C. https://orcid.org/0000-0002-4106-3396
Makowski, Liza https://orcid.org/0000-0002-5337-8037
Funding for this research was provided by:
Mark Foundation For Cancer Research
U.S. Department of Veterans Affairs (IK6 BX005649)
National Cancer Institute (U01CA272541, U01CA272541)
Article History
Received: 30 December 2024
Accepted: 12 February 2025
First Online: 14 March 2025
Competing interests
: J.C.R. is a founder and consultant for Sitryx Therapeutics. All others declare no competing interests.